Company intelligence / Profile preview

Binacea Pharma

Hayward, California, United Statesbinaceapharma.com ↗

Ownership: Private
Development stage: Other

Overview

Currently conducting a Phase 1 dose escalation study (NCT05150457) to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of BNA035 in patients with advanced solid tumors. The study aims to determine the maximum tolerated dose (MTD) and Recommended Phase 2 dose (RP2D).

Therapeutic areas: OncologyImmunology
Modalities: Antibody drugsBispecific antibodiesNanobody
Industry: Biotech

Drug pipeline

1 asset

HLX35

IND

Indications: Advanced malignant solid tumors

Partnerships

Henlius Biotech (licensed HLX35, an anti-EGFR and anti-4-1BB bispecific antibody)

Beyond the preview

Go deeper on Binacea Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Binacea Pharma.

Explore the full profile